Shares in biotech company Recursion Pharmaceuticals (RXRX 12.07%) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.
The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (RLYB 42.13%). REV102 is being developed to treat hypophosphatasia (HPP) -- a rare and debilitating genetic disorder that affects bone development.
According to Recursion, "HPP is a devastating genetic disorder affecting over 7,800 diagnosed patients across the U.S. and major European countries." It targets an enzyme, ENPP1, whose inhibition is believed to help treat HPP.
Until today, Recursion and Rallybio have had a joint venture to develop ENPP1 inhibitors, which have resulted in REV102, still in the preclinical stage of development.
The deal is good news for both companies. Focusing on Rallybio, the company will receive:
Meanwhile, Recursion gains full ownership of REV102 and can now develop the drug without worrying about Rallybio's consideration of the matter.
Image source: Getty Images.
The agreement helps de-risk the development of REV102 and removes uncertainty around it in connection with Rallybio's financial condition. That's a plus and adds value to Recursion's pipeline, even if REV102 is in a very early stage of development.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。